{"id":"methylphenidate-hydrochloride-extended-release-tablets","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Insomnia"},{"rate":"5-10%","effect":"Dry mouth"},{"rate":"5-10%","effect":"Anxiety"}]},"_chembl":{"chemblId":"CHEMBL1722","moleculeType":"Small molecule","molecularWeight":"269.77"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It does this by inhibiting the reuptake of these neurotransmitters, allowing them to remain in the synaptic cleft for a longer period and increasing their activity. This leads to increased alertness, attention, and energy.","oneSentence":"Methylphenidate hydrochloride is a central nervous system stimulant that works by increasing the levels of dopamine and norepinephrine in the brain.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:49:55.668Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Attention deficit hyperactivity disorder (ADHD)"}]},"trialDetails":[{"nctId":"NCT07314333","phase":"PHASE1","title":"A Trial to Assess How Centanafadine Interacts With Stimulants in the Body","status":"RECRUITING","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2026-02-05","conditions":"ADHD","enrollment":42},{"nctId":"NCT06369714","phase":"NA","title":"Neurofeedback-Based Digital Therapeutics for the Diagnosis and Treatment of ADHD in Children.","status":"RECRUITING","sponsor":"Lei Lei, MD","startDate":"2023-02-24","conditions":"Attention Deficit Disorder With Hyperactivity, Executive Function Disorder","enrollment":210},{"nctId":"NCT05957055","phase":"PHASE2","title":"Lisdexamphetamine Vs Methylphenidate for Pediatric Patients with ADHD and Type 1 Diabetes","status":"RECRUITING","sponsor":"Medical University of Lodz","startDate":"2024-02-05","conditions":"Attention Deficit Disorder with Hyperactivity, Diabetes Mellitus, Type 1","enrollment":150},{"nctId":"NCT04507204","phase":"PHASE4","title":"Real-World Evidence of Duration of Effect of Adhansia XR (Extended-Release) for Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD)","status":"TERMINATED","sponsor":"Purdue Pharma LP","startDate":"2020-07-30","conditions":"Attention-Deficit/Hyperactivity Disorder","enrollment":267},{"nctId":"NCT03811847","phase":"PHASE4","title":"A Pilot of Methylphenidate in Mild Cognitive Impairment and Dementia Participants.","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2019-11-01","conditions":"Alzheimer Dementia","enrollment":11},{"nctId":"NCT00901576","phase":"PHASE1","title":"A Drug Interaction Study of SPD503 and Concerta Administered Alone and In Combination in Normal Healthy Volunteers","status":"COMPLETED","sponsor":"Shire","startDate":"2009-05-18","conditions":"Healthy","enrollment":38},{"nctId":"NCT04138498","phase":"PHASE1, PHASE2","title":"CTx-1301 Comparative Bioavailability Study","status":"COMPLETED","sponsor":"Cingulate Therapeutics","startDate":"2019-12-06","conditions":"ADHD","enrollment":45},{"nctId":"NCT01238575","phase":"PHASE4","title":"Guanfacine for the Treatment of Hyperactivity in Pervasive Developmental Disorder","status":"COMPLETED","sponsor":"Yale University","startDate":"2011-12","conditions":"Pervasive Development Disorders","enrollment":62},{"nctId":"NCT02536105","phase":"NA","title":"PK/PD Pediatric ADHD Classroom Study","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2016-05","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":88},{"nctId":"NCT03546400","phase":"PHASE4","title":"Safety, Tolerability and PK Study of Methylphenidate HCl ERCT in 4-5 Year Old Children With ADHD.","status":"WITHDRAWN","sponsor":"Pfizer","startDate":"2018-09-25","conditions":"Attention Deficit Hyperactivity Disorder (ADHD)","enrollment":""},{"nctId":"NCT03536390","phase":"PHASE4","title":"A 6-week Study to Evaluate the Safety and Efficacy of Methylphenidate HCl ERCT in 4-5 Year Old Children With ADHD","status":"WITHDRAWN","sponsor":"Pfizer","startDate":"2018-09-19","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":""},{"nctId":"NCT03580005","phase":"PHASE4","title":"A 6-week Study to Evaluate the Safety and Efficacy of Quillichew ERCT in 4-5 Year Old Children With ADHD.","status":"WITHDRAWN","sponsor":"Pfizer","startDate":"2018-10-31","conditions":"Attention Deficit Hyperactivity Disorder (ADHD), Attention Deficit Hyperactivity Disorder","enrollment":""},{"nctId":"NCT01835548","phase":"PHASE3","title":"NT0102 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)","status":"COMPLETED","sponsor":"Neos Therapeutics, Inc","startDate":"2013-07","conditions":"Attention Deficit Hyperactivity Disorder (ADHD)","enrollment":87},{"nctId":"NCT01624649","phase":"","title":"A Study to Examine the Progression of Attention-Deficit Hyperactivity Disorder (ADHD) Drug Treatment and to Analyze Associated Factors","status":"COMPLETED","sponsor":"Janssen Korea, Ltd., Korea","startDate":"2012-02","conditions":"Attention-deficit Hyperactivity Disorder","enrollment":289},{"nctId":"NCT00922636","phase":"PHASE2, PHASE3","title":"A Study of Pediatric Patients With Attention Deficit/Hyperactivity Disorder","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2009-06","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":340},{"nctId":"NCT00307684","phase":"PHASE3","title":"Open Label, Multicentre Extension Study of Protocol 42603ATT3002 to Evaluate Safety of Prolonged Release OROS Methlyphenidate in Adults With Attention Deficit Hyperactivity Disorder (ADHD)","status":"COMPLETED","sponsor":"Janssen-Cilag International NV","startDate":"2006-01","conditions":"Attention Deficit Disorder With Hyperactivity","enrollment":155},{"nctId":"NCT00937040","phase":"PHASE4","title":"Adult Study / OROS Methylphenidate Hydrochloride (HCL) (OROS MPH) in Adults With Attention Deficit Hyperactivity Disorder (ADHD)","status":"COMPLETED","sponsor":"Ortho-McNeil Janssen Scientific Affairs, LLC","startDate":"2009-07","conditions":"Attention Deficit Disorder With Hyperactivity","enrollment":357},{"nctId":"NCT00326300","phase":"PHASE3","title":"A Long-Term Safety Study to Evaluate Methylphenidate HCL Tablets at Multiple Dose Levels in Adults With Attention Deficit Hyperactivity Disorder","status":"COMPLETED","sponsor":"McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.","startDate":"2006-04","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":560},{"nctId":"NCT00326391","phase":"PHASE3","title":"A Safety and Effectiveness Study of Methylphenidate HCl Extended-release Tablets in Adults With Attention Deficit Hyperactivity Disorder","status":"COMPLETED","sponsor":"McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.","startDate":"2006-04","conditions":"Attention Deficit Disorder With Hyperactivity","enrollment":229}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"methylphenidate hydrochloride extended-release tablets","genericName":"methylphenidate hydrochloride extended-release tablets","companyName":"McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.","companyId":"mcneil-consumer-specialty-pharmaceuticals-a-division-of-mcneil-ppc-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Methylphenidate hydrochloride extended-release tablets are used to treat Attention Deficit Hyperactivity Disorder (ADHD). They work by affecting the levels of certain neurotransmitters in the brain, specifically dopamine and norepinephrine, which are involved in attention and impulse control.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}